# IPH6501 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/iph6501

> IPH6501, sponsored by Innate Pharma SA (IPHA): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | IPH6501 |
| Codes | IPH6501 |
| Sponsor | Innate Pharma SA (IPHA) https://sec-api.dev/companies/ipha/catalysts |
| Indications | relapsed and/or refractory cd20-expressing b-cell non-hodgkin's lymphoma |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### March 6, 2024: trial start

- Status: completed. Date confidence: exact. Stage: 1/2. Indication: Relapsed and/or Refractory CD20-expressing B-cell non-Hodgkin's lymphoma.
- First seen 2025-03-27, last confirmed 2025-04-30.
- Press release filed with the SEC (EX-99) (accession 0001598599-25-000023): "In March 2024 the first patient was dosed in the Phase 1/2 clinical trial evaluating IPH6501 in B cell Non-Hodgkin's lymphoma (B-NHL)." https://www.sec.gov/Archives/edgar/data/1598599/000159859925000023/exhibit991-250327.htm
- SEC Form 10-K (accession 0001598599-25-000042): "On March 6, 2024, the Company announced that the first patient was dosed in its Phase 1/2 multicenter trial (NCT06088654), investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell non-Hodgkin's lymphoma." https://www.sec.gov/Archives/edgar/data/1598599/000159859925000042/inpha-20241231.htm
- SEC Form 10-K (accession 0001598599-25-000042): "On March 6, 2024, the Company announced the first patient was dosed in its Phase 1/2, investigating the safety and tolerability of IPH6501, a first-in-class CD20-targeting tetraspecific natural killer cell engager, from ANKET® platform, in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma." https://www.sec.gov/Archives/edgar/data/1598599/000159859925000042/inpha-20241231.htm

### Jun 2024: trial start

- Status: completed. Date confidence: month.
- First seen 2025-04-30, last confirmed 2026-03-26.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-021168): "The €0.4 million increase in expenses related to the IPH6501 program reflects the advancement of clinical activities; as a reminder, this program entered clinical development after the first patient was dosed in June 2024." https://www.sec.gov/Archives/edgar/data/1598599/000162828026021168/a200326exhibit991.htm
- SEC Form 10-K (accession 0001598599-25-000042): "Following first patient dosed in June 2024, this program is now in clinical stage therefore we have reclassed 2023 expenses in the sub-total programs in clinical development" https://www.sec.gov/Archives/edgar/data/1598599/000159859925000042/inpha-20241231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/iph6501.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IPH6501 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/iph6501

```bibtex
@misc{secapidev_pdufa_iph6501_20261116,
  title        = {IPH6501 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/iph6501}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_iph6501_20261116","title":"IPH6501 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/iph6501","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
